classified and analysed according to the underlying genetic cause.
Introduction 1
Childhood mitochondrial diseases have a heterogeneous phenotype with many 2 different systems being affected including the peripheral nervous system. Around 30% of 3 children with a mitochondrial disease have an associated peripheral neuropathy (Colomer, et 4 al., 2000) , but the neuropathy is often unrecognised due to the overwhelming central nervous 5 system manifestations. Mutations in nuclear genes responsible for mitochondrial dynamics 6 and axonal transport, including MFN2 and GDAP1, are recognised causes of Tooth disease (CMT) (Niemann, et al., 2005; Züchner, et al., 2004) . Recently, mutations in 8 MT-ATP6 and SURF1, genes known to cause Leigh syndrome and other multisystemic 9 mitochondrial diseases, have also been shown to cause phenotypes characterised 10 predominantly by a peripheral neuropathy (Echaniz-Laguna, et al., 2013; Pitceathly, et al., 11 2012) . Identifying the presence of a peripheral neuropathy and defining its characteristics child in the prospective study also had data included from another nerve conduction study Nerve conduction studies in the two youngest patients showed a demyelinating motor 14 neuropathy. Nerve conduction studies in the older children invariably showed a severe axonal 15 sensory neuropathy, irrespective of the age at which the studies were performed, with three of 16 the older children having additional motor nerve involvement.
18

SURF1 (Surfeit 1)
19
Eleven nerve conduction studies from 10 children (from nine families; individuals 16 20 and 23 were siblings) with homozygous or compound heterozygous SURF1 mutations were 21 included in this study (Table 3) . Seven of the children described here (patients 16, 17, 18, 19, 22 20, 22, 23) were also included in a description of 44 individuals with SURF1 mutations by 23 Wedatilake et al (Wedatilake, et al., 2013) . Presentation was between three days and 18 24 months of age with poor feeding, vomiting and poor weight gain. The associated neuropathy was usually evident by 18 months of age with gait ataxia and tremor in the upper limbs. Other 1 common features included growth failure, developmental regression, nystagmus and lactic 2 acidemia. Brain MRI showed changes consistent with Leigh syndrome in all except one child 3 who had a normal MRI at one year of age. Reduced or absent cytochrome c oxidase (COX) 4 activity in muscle or cultured fibroblasts was seen in all nine children who had this tested.
5
Nine of the children died between 20 months and seven years of age and one child was alive 6 at 12 years. Seven children had a demyelinating neuropathy, with four having sensorimotor 9 involvement and three isolated motor involvement. Three studies showed predominantly 10 axonal changes with a mild reduction in motor conduction velocity. Unlike typical forms of 11 CMT, the nerve conduction abnormalities were not length-dependent. Three children had 12 only motor involvement on nerve conduction studies. (Table 4) . Sensory responses were universally absent, 24 even in studies done at a young age.
Discussion
1
Normal mitochondrial function is essential for neuronal growth, function and survival 2 (Sheng, 2014) . The genes that affect mitochondrial function may cause peripheral neuropathy 3 by alteration in the mitochondrial dynamics of fusion, fission and axonal transport, or due to 4 abnormalities in energy production. (Cassereau, et al., 2009; Chen, et al., 2003; Hollenbeck 5 and Saxton, 2005; Misko, et al., 2010; Sheng and Cai, 2012; Song, et al., 2009; Vallat, et al., 6 2008). The neuropathy associated with CMT is usually length-dependent, with weakness 7 starting and being more pronounced distally, and the lower limbs being affected earlier and 8 more severely than the upper limbs. Neurophysiology in CMT often parallels this clinical 9 picture with axonal degeneration (primary in CMT2 and secondary to a demyelinating 10 process in CMT1), as measured by the CMAP and SNAP amplitudes, of greater severity in 11 the lower limbs Scherer, 1999) . In contrast, 12 this study shows that the nerve conduction abnormalities in children with mitochondrial 13 disease are generally not length-dependent. external ophthalmoplegia, the presence of a peripheral neuropathy had the highest specificity 21 (91%), negative predictive value (83%) and positive likelihood ratio (5.87) for the diagnosis 22 of a nuclear DNA defect, as opposed to a mitochondrial gene defect (Horga, et al., 2014) . had only borderline reductions in peroneal CMAP amplitudes (Kaufmann, et al., 2006b (Rahman, et al., 1996) . In individuals with the NARP phenotype, the presence of a peripheral 10 neuropathy in the first two decades of life is specific to the m.9185T>C mutation (Childs, et 11 al., 2007) . Peripheral neuropathy is uncommon with single large mitochondrial deletions and 12 has been described in only a single case report (McDonald, et al., 2002 (Hakonen, et al., 2005; Neeve, et al., 2012; Schulte, et al., 2009), 21 although an earlier onset has occasionally been described (Tzoulis, et al., 2006; Wong, et al., 22 2008). While hypotonia and areflexia are listed as features of POLG mutations in the first 23 year of life, there are very few reports of the nerve conduction findings of affected children.
24
Our study included two young children with POLG mutations and demyelinating motor neuropathies. In a cohort of eight children with Alpers syndrome and POLG mutations, 1 Ferrari et al. reported two infants with neurophysiological or biopsy evidence of a 2 demyelinating neuropathy (Ferrari, et al., 2005) . Recessive mutations in PEO1, the gene 3 encoding mitochondrial Twinkle helicase, present with a similar phenotypic spectrum to 4 POLG and are also associated with an early-onset sensory neuropathy (Lönnqvist, et al., 5 2009). (Garone, et al., 2011; Hirano, et al., 2004 (Bonne, et al., 1993; Chabrol, et 22 al., 1994; Di Rocco, et al., 2000; Federico, et al., 1990; Koga, et al., 2012; Marsac, et al., 23 1997) . In these reports, the axonal neuropathy was recognised in both those investigated prior 24 to institution of treatment with thiamine as well as those on treatment. Only a single individual had a more significant reduction of median motor conduction velocity, which 1 improved from 19.8m/s to 37.9m/s following treatment with thiamine (Di Rocco, et al., 2 2000) . Long term treatment with dicholoroacetate, used to treat lactic acidosis in children 3 with PDHc deficiency, has been shown to cause a reversible axonal neuropathy and animal 4 studies have shown that thiamine may mitigate the severity of this neuropathy (Berendzen, et 5 al., 2006; Kaufmann, et al., 2006a; Stacpoole, et al., 1990) . 
Acute neuropathy with mitochondrial disease 8
An acute neuropathy has only rarely been described in mitochondrial disease (Coker, 9 1993; Hara, et al., 1994; Stickler, et al., 2003) . In our study, one child with MELAS 10 developed an acute axonal neuropathy during an acute stroke-like episode. Acute reversible 11 axonal dysfunction related to energy failure in peripheral nerves has been shown to occur 12 during stroke-like episodes in MELAS (Farrar, et al., 2010) . It is possible that an acute 13 neuropathy accompanies stroke-like episodes in MELAS but is under-recognised due to the 14 prominent central nervous system features. In our study, two children with PDHc deficiency 15 had evidence of an axonal sensorimotor neuropathy on studies performed when they were not 16 acutely ill. Debray et al. described 13 individuals with PDHc deficiency and acute weakness.
17
Of the seven who had undergone nerve conduction studies, five had evidence of a peripheral 18 neuropathy (Debray, et al., 2006) . The lack of nerve conduction studies before the onset of 19 weakness or after recovery makes it difficult to determine if the neuropathy was chronic or if 20 an acute metabolic neuropathy or worsening of a pre-existing neuropathy was responsible for 21 the acute weakness.
22
The combination of retrospective and prospective data is a limitation of this study, Abnormal results (< 2SD) in bold. Reference values from Cai et al. (Cai and Zhang, 1997) . Hz -homozygous, w-weeks, m-months, y-years, R -retrospective, P -prospective, CMAP -compound muscle action potential, CV -conduction velocity, SNAP -sensory nerve action potential, M -median, U -ulnar, P -peroneal, T -tibial, S -sural, Sp -superficial peroneal, Mp -medial plantar, NR -not recordable, NA -not available, sup -superficial, empty box indicates this nerve was not studied 
Abnormal results (< 2SD) in bold. Reference values from Cai et al. (Cai and Zhang, 1997) . Hz -homozygous, w-weeks, m-months, y-years, R -retrospective, P -prospective, CMAP -compound muscle action potential, CV -conduction velocity, SNAP -sensory nerve action potential, M -median, U -ulnar, P -peroneal, T -tibial, S -sural, Sp -superficial peroneal, Mp -medial plantar, NR -not recordable, NA -not available, sup -superficial, empty box indicates this nerve was not studied Abnormal results (< 2SD) in bold. Reference values from Cai et al. (Cai and Zhang, 1997) . Hz -homozygous, w-weeks, m-months, y-years, R -retrospective, P -prospective, CMAP -compound muscle action potential, CV -conduction velocity, SNAP -sensory nerve action potential, M -median, U -ulnar, P -peroneal, T -tibial, S -sural, Sp -superficial peroneal, Mp -medial plantar, NR -not recordable, NA -not available, sup -superficial, empty box indicates this nerve was not studied (P) 1.9/47 (T) 2.5/37 (Cai and Zhang, 1997) . Hz -homozygous, w-weeks, m-months, y-years, R -retrospective, P -prospective, CMAP -compound muscle action potential, CV -conduction velocity, SNAP -sensory nerve action potential, M -median, U -ulnar, P -peroneal, T -tibial, S -sural, Sp -superficial peroneal, Mp -medial plantar, NR -not recordable, NA -not available, sup -superficial, empty box indicates this nerve was not studied
SUPPLEMENTARY METHODS
Nerve conduction tests
Nerve conduction tests were performed using a Viking™ On Nicolet™ EDX Electrodiagnostic System from CareFusion Nicolet with surface electrodes. Sedation with nitrous oxide was used in some children above the age of 12 months. For the motor studies, a supramaximal rectangular pulse direct current stimulus was delivered using a two-prong stimulator, to elicit a compound muscle action potential (CMAP). The median nerve was stimulated at the wrist and elbow and the CMAP was recorded over the bulk of the abductor pollicis brevis (APB) muscle. The ulnar nerve was stimulated over the wrist and behind the elbow and the CMAP was recorded over the bulk of the abductor digiti minimi (ADM) muscle. The common peroneal nerve was stimulated over the ankle and knee and the CMAP was recorded over the bulk of the extensor digitorum brevis (EDB) muscle. The tibial nerve was stimulated over the ankle and behind the knee and the CMAP was recorded over the bulk of the abductor hallucis (AH) muscle. The sweep speed and sensitivities were 5 ms/division and 5 mV/division respectively. The duration of the stimulus was 0.1ms.
The sensory nerve action potential (SNAP) was recorded by an orthodromic technique for the upper limb (median and ulnar) nerves and by an antidromic technique for the lower limb (sural) nerve. For the median nerve, the stimulus was delivered by ring electrodes over the index finger (digital branch of the median nerve) and SNAPs were recorded over the wrist.
For the ulnar nerve, the stimulus was delivered by ring electrodes over the little finger (digital branch of the ulnar nerve) and SNAPs were recorded over the wrist. For the sural nerve, the stimulus was delivered above the lateral malleolus, approximately 14 cm from the proximal recording electrode which was placed on the lateral border of the foot. All sensory potentials were recorded using a recurrent stimulus and with averaging using a supramaximal stimulus.
The stimulus duration was 0.1ms and the sweep speed and sensitivities were 1 ms/division and 10 µV/division respectively.
